Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms ERD 1233, ERD1233 |
Target |
Action degraders |
Mechanism ERs degraders(Estrogen receptors degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Estrogen receptor positive breast cancer | Preclinical | United States | 01 Nov 2024 |